GH Research (GHRS) EBT (2020 - 2025)
GH Research's (GHRS) quarterly EBT came in at -$13.5 million in Q4 2025, down 22.21% year-on-year from -$17.3 million in Q4 2024, and up 3.86% quarter-over-quarter from -$14.0 million in Q3 2025.
GH Research (GHRS) EBT (2020 - 2025) Analysis & Trends
GH Research's EBT history runs 6 years deep, the most recent figure standing at -$13.5 million for Q4 2025.
- On a quarterly basis, EBT fell 22.21% year-over-year to -$13.5 million in Q4 2025; TTM through Dec 2025 was -$47.6 million, a 15.57% decrease from a year earlier, with the FY2025 full-year figure at -$47.6 million, down 15.57% from the prior year.
- EBT rose to -$13.5 million in Q4 2025 per GHRS's latest filing, from -$14.0 million in the prior quarter.
- Across five years, EBT topped out at $334000.0 in Q2 2022 and bottomed at -$16.6 million in Q4 2022.
- The 5-year median for EBT is -$8.3 million (2023), against an average of -$7.7 million.
- Across the five-year window, EBT tumbled 2961.67% in 2021 and surged 115.72% in 2022, its largest moves.
- Year by year, EBT stood at -$4.1 million in 2021, then sank by 305.43% to -$16.6 million in 2022, then surged by 46.71% to -$8.8 million in 2023, then dropped by 24.78% to -$11.0 million in 2024, then slipped by 22.21% to -$13.5 million in 2025.
- Per Business Quant, the three latest GHRS EBT figures stand at -$13.5 million (Q4 2025), -$14.0 million (Q3 2025), and -$9.3 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -9.29 Mn |
| Mar 31, 2025 | -10.81 Mn |
| Dec 31, 2024 | -11.03 Mn |
| Sep 30, 2024 | -12.11 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -7.67 Mn |
| Dec 31, 2023 | -8.84 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -16.59 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | 334,000.00 |
| Mar 31, 2022 | -5.76 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | -1.84 Mn |
| Jun 30, 2021 | -2.13 Mn |
| Mar 31, 2021 | -1.15 Mn |